Fulcrum Therapeutics Q3 EPS $(0.31) Misses $(0.29) Estimate; Cash $200.6M
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 3.13 percent increase over losses of $(0.32) per share
